Management and Grading of EGFR Inhibitor-Induced Cutaneous Toxicity | Zendy

J Beech | Zendy; Theodora Germetaki | Zendy; Mary Judge | Zendy; Nina Paton | Zendy; J. M. Collins | Zendy; Abigail Garbutt | Zendy; Michael Braun | Zendy; J Fenwick | Zendy; Mark Saunders | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management and Grading of EGFR Inhibitor-Induced Cutaneous Toxicity

Author(s) -

J Beech,

Theodora Germetaki,

Mary Judge,

Nina Paton,

J. M. Collins,

Abigail Garbutt,

Michael Braun,

J Fenwick,

Mark Saunders

Publication year - 2018

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2018-0187

Subject(s) - medicine , grading (engineering) , colorectal cancer , medical prescription , quality of life (healthcare) , health professionals , chemotherapy , intensive care medicine , oncology , health care , cancer , pharmacology , nursing , civil engineering , engineering , economics , economic growth

Cutaneous toxicities associated with EGFR inhibitors (EGFRIs) have a significant impact on patient treatment continuation, quality of life and healthcare resource utilization. This paper reviews the current prophylaxis and management of EGFRI-induced cutaneous toxicities in patients with colorectal cancer, and combines these findings with the authors’ clinical expertise to define a novel algorithm for healthcare professionals managing patients receiving EGFRIs. This tool includes a grading system based on the location, severity and psychological impact, and provides a standard prescription pack, advice on prophylaxis/self-management of cutaneous symptoms for patients initiating EGFRIs, and essential guidance on subsequent review and treatment escalation. It aims to optimize treatment of metastatic colorectal cancer by minimizing cutaneous toxicities to maintain dose intensity and efficacy of EGFRI-based chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research